Rah. Adan et T. Vink, Drug target discovery by pharmacogenetics: mutations in the melanocortin system and eating disorders, EUR NEUROPS, 11(6), 2001, pp. 483-490
The identification of the genetic defect underlying the obese phenotype of
the viable yellow mouse, ectopic overexpression of the agouti protein which
act, as antagonist at the melanocortin-4 receptor, together with the demon
stration that the brain melanocortin system was one major downstream effect
or pathway of leptin signaling has put forward melanocortin receptors as dr
ug targets for obesity, The lack of compounds acting as melanocortin recept
or antagonists was the reason why pharmaco logical studies had not recogniz
ed melanocortin receptors as important drug targets earlier. Blockade of br
ain melanocortin receptors results in increased food intake and body weight
, whereas stimulation of the brain melanocortin system results in decreased
food intake and activation of the hypothalamo-pituitary-adrenal axis. Anor
exia nervosa is characterized by decreased body weight and food intake acco
mpanied by changes in neuroendocrine systems such as strong activation of t
he hypothalamo-pituitary-adrenal axis. Since agouti-related protein suppres
ses the activity of the melanocortin system, the AgRP gene was investigated
as candidate gene in anorexia nervosa. One variant of the AgRP gene was as
sociated with anorexia nervosa. thus putting forward melanocortin receptor
blockade as putative pharmacotherapy. Investigating variations in candidate
genes in disease populations appears to be a fruitful approach towards the
identification of drug targets. (C) 2001 Published by Elsevier Science B.V
.